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Abstract
The appearance of lung metastases is associated with poor outcome and the management of patients with
secondary pulmonary tumours remains a clinical challenge. We examined the vascularization process of lung
metastasis in six different preclinical models and found that the tumours incorporated the pre-existing alveolar
capillaries (ie vessel co-option). During the initial phase of vessel co-option, the incorporated capillaries were
still sheathed by pneumocytes, but these incorporated vessels subsequently underwent different fates dependent
on the model. In five of the models examined (B16, HT1080, HT25, C26, and MAT B-III), the tumour cells
gradually stripped the pneumocytes from the vessels. These dissected pneumocytes underwent fragmentation,
but the incorporated microvessels survived. In the sixth model (C38), the tumour cells failed to invade the alveolar
walls. Instead, they induced the development of vascularized desmoplastic tissue columns. Finally, we examined
the process of arterialization in lung metastases and found that they became arterialized when their diameter grew
to exceed 5mm. In conclusion, our data show that lung metastases can vascularize by co-opting the pulmonary
microvasculature. This is likely to have important clinical implications, especially with respect to anti-angiogenic
therapies.
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Introduction
Metastasis – the dissemination of malignant cells from
a primary tumour to distant sites – is the main cause
of death in many cancers, including breast, colorec-
tal, melanoma, pancreatic, renal, and ovarian cancer.
The lung is a frequently involved site in metastatic
disease [1], with metastases found in 20–54% of
extrathoracic tumours [2–4]. The only method that so
far has demonstrated a real potential to treat patients
with lung metastasis is surgical metastasectomy [5].
A report summarizing the data of more than 5000
patients identified resectability, the number of metas-
tases, disease-free interval after surgery, and histology
as important prognostic factors for lung metastasectomy
[6]. Unfortunately, however, most patients with lung
metastasis are not eligible for surgery and are managed
with systemic or locoregional chemo- and/or targeted
therapies, the efficacy of which is still modest [7–9].
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Access to a sufficient blood supply is considered
essential for the growth of metastases [10]. The study
of the tumour vasculature in metastases is important
for several reasons. Firstly, the effective delivery of
any given anti-cancer drug is dependent on the pres-
ence of an efficient tumoural blood supply and is influ-
enced by heterogeneities in the blood supply between
different intratumoural areas [11]. Secondly, conven-
tional drugs designed to target the tumour vasculature
(ie anti-angiogenic agents) have shown mixed and often
disappointing results in the treatment of metastatic can-
cer [12–15]. Therefore, a better understanding of the
tumour vascularization process in metastases is criti-
cal for the development of more successful therapeutic
strategies for treating metastatic disease.
Based on early observations on tumours growing
in artificial locations such as the subcutaneous space,
tumour vascularization had been long considered to
require sprouting angiogenesis [16–18]. The first
description of a so-called alternative (ie non-sprouting)
tumour vascularization mechanism [10] dates back
to the mid-1990s, when Pezzella et al published their
groundbreaking work on non-angiogenic primary
[19] and metastatic [20] lung tumours that grow by
exploiting the pre-existing lung vasculature. These
studies in human pathology provided evidence that
both non-small cell lung cancer (NSCLC) [19] and
pulmonary metastases of breast cancer [20] can develop
and progress in the absence of neo-angiogenesis by
co-opting the alveolar capillaries. Subsequent human
studies from Pezzella and co-workers [21,22] and other
groups [23,24] have confirmed the phenomenon of ves-
sel co-option in non-angiogenic primary and secondary
lung tumours and, moreover, in various other primary
andmetastatic humanmalignancies (reviewed in ref 25).
Nevertheless, the exact mechanism of vessel co-option
in lung metastasis has been largely unexplored.
Here, by using confocal microscopy, electron
microscopy, and a two-colour corrosion casting tech-
nique, we studied the tumour vascularization process in
six different preclinical models of lung metastasis. Our
results provide the first direct experimental evidence
that pulmonary metastases can vascularize via co-opting
the pre-existing pulmonary vasculature. Our study also
presents the detailed mechanism of this process and,
moreover, demonstrates that lung metastases develop a
bronchial (ie arterial) blood supply during their growth.
These findings are likely to have important implications
with respect to the treatment of lung metastasis.
Materials and methods
Tumour cell lines and experimental lung metastases
The HT1080 human fibrosarcoma, HT25 human colon
carcinoma, C26 murine colon carcinoma, MAT-B-III
rat mammary carcinoma, and B16 mouse melanoma
cell lines were cultured in RPMI-1640 medium sup-
plemented with 10% fetal bovine serum (catalogue
Nos R8758 and F4135, respectively; Sigma-Aldrich, St
Louis, MO, USA). C38 murine colon carcinoma cells
were maintained by serial subcutaneous transplantations
in C57Bl/6 mice. A detailed description of the pul-
monary metastasis models may be found in the Supple-
mentary materials and methods.
Immunofluorescence analysis, tumour
and endothelial cell proliferation, and electron
microscopy
The immunofluorescence methods and electron micro-
scopic analysis of lung metastases performed on B16
and HT1080 tumour lines may be found in the Sup-
plementary materials and methods and Supplementary
Table 1.
Vascular corrosion casting: determination of the
percentage of arterial metastases and the size
of the metastases
In contrast to the mouse lung, which does not have a
functional intraparenchymal bronchial arterial vascula-
ture, the existence of such a circulatory system in the
rat lungs is proven [26,27]. Consequently, these exper-
iments were carried out in rats carrying pulmonary
metastases of MAT-B-III cells. To determine the size
of the metastases and to investigate the origin of their
blood supply, we used a two-colour corrosion casting
procedure described previously [28] and presented in the
Supplementary materials and methods.
Results
Preservation of alveolar architecture in the
peripheral regions of lung metastases that is
indicative of vessel co-option
We studied the process of tumour vascularization in
six different models of experimental lung metastasis.
Experimental lung metastases were generated by inject-
ing HT1080, HT25, B16 or C26 cells intravenously into
mice or, in the case of MAT-B-III, into mice or rats.
Experimental lung metastases of C38 cells were gen-
erated using a spontaneous model of lung metastasis
involving the injection of tumour cells into the footpad
of the hind leg. The size of the metastatic lung nod-
ules that we studied ranged from 100 μm up to several
millimetres. Larger tumours (>5mm in diameter) were
observed in rats injected with MAT-B-III. The mecha-
nism of vascularization that we observed was indepen-
dent of tumour size.
After extravasation and forming small interstitial
colonies (ie growth of tumour cells within the alveolar
walls), tumour cells proceeded to enter the alveolar
air spaces. The expansion from one alveolar space to
another was the default pattern for all of the tumour cell
lines studied (Figures 1A and 1B). This was evident
because the normal structure of the alveolar walls, which
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Figure 1. Preservation of alveolar architecture in the peripheral regions of lung metastases that is indicative of vessel co-option. (A)
Low-power micrograph of a MAT-B-III lung metastasis from a SCID mouse. The section is stained for the pneumocyte marker podoplanin
(green), the EC marker CD31 (red), and TOTO-3 (blue), which highlights the tumour mass. The alveolar air spaces are filled with tumour
cells at the tumour periphery (arrows). An asterisk marks the centre of the metastasis. Scale bar= 200 μm. (B) Micrograph of a C38 lung
metastasis stained for CD31 (green) and laminin (red) from a C57BL/6 mouse. Normal lung parenchyma is present on the left (arrowheads
mark the border of the metastasis). Tumour cells occupy the alveolar air spaces and expand them. Accordingly, the closer the alveolus is
to the tumour centre, the larger the lumen becomes. Scale bar= 200 μm. (C) Periphery of a MAT-B-III metastasis in a mouse lung stained
for podoplanin (green), CD31 (red), and with TOTO-3 (blue). Tumour cells fill the alveoli. Pneumocytes line the surface of the alveoli in a
regular manner (arrows). Scale bar= 20 μm. (D) High-power confocal micrograph of the periphery of an HT1080 lung metastasis formed
in a SCID mouse stained for podoplanin (green), CD31 (red), and with TOTO-3 (blue). Note that intact alveolar walls with regular layering
(pneumocyte–capillary–pneumocyte) are present (arrows). Scale bar= 10 μm. (E) Low-power electron micrograph captured at the periphery
of a B16 lung metastasis from a C57BL/6 mouse. Tumour cells (tu), which are recognizable due to the presence of melanocytic granules
(arrowheads), are seen filling the alveolar air space, whilst the adjacent capillary lumens (cap) are free of tumour cells. Two white blood
cells are visible in the lumen of the capillary on the right. The plasma membrane of a tumour cell makes close contact with the pneumocyte
plasma membrane over a large surface area (arrows). Asterisks mark areas where the alveolar lumen is filled with protein-containing liquid.
Scale bar= 2 μm. (F). High-power electron micrograph at the periphery of an HT1080 lung metastasis from a SCID mouse showing a capillary
(cap) surrounded by tumour cells (tu). On both sides of the capillary, a normal blood–gas barrier is present consisting of a pneumocyte layer
(pn), a basement membrane (bm), and an endothelial layer (ec). Scale bar= 1 μm.
are composed of blood vessels and a sheathing layer of
pneumocytes on either side, was strikingly preserved
at the periphery of the tumour mass (Figures 1C and
1D). Alveolar walls present within the tumour were also
examined at the electron microscopy level. We found
that the blood–gas barrier of the normal lung, which
consists of an endothelial cell (EC) layer, a basement
membrane (BM), and an epithelial layer, was preserved
at the peripheral tumour areas (Figures 1E and 1F).
The lumens of the incorporated capillaries were free of
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tumour cells (Figures 1E and 1F). These data indicate
that the tumour cells gained access to a vascular supply
by co-opting the normal alveolar capillaries.
Tumour cells strip the alveolar epithelium from
co-opted vessels
In all the models examined but one (the C38 colorectal
cancer model, described later), ‘naked’ microvessels
surrounded by tumour cells (ie blood capillaries not
sheathed by a layer of pneumocytes) could be detected
100–200 μm inwards from the invasive edge of the
metastases (Supplementary Figure 1A). The appearance
of these pneumocyte-free blood capillaries occurred
due to a unique process instigated by the tumour cells
themselves. Tumour cells infiltrated into the alveolar
walls and invaded in between the capillaries and the
alveolar epithelium (Supplementary Figure 1B). This
resulted in detachment of the pneumocytes from the
underlying capillaries (Supplementary Figures 1C and
1E). We used electron microscopy to examine this
process at higher resolution and observed tumour cells
in the process of separating pneumocytes from ECs.
For example, a B16 melanoma cell could be seen
extending a protrusive structure that physically drives
a wedge between the pneumocyte and the adjacent EC
(Figures 2A and 2B). During this process, the BM of the
blood–gas barrier was separated into an EC-associated
BM layer and an epithelial-associated BM layer
(Figures 2A and 2B). After splitting occurred, the
tumour cells attached firmly to both the EC-associated
BM layer and the epithelial-associated BM layer
(Figures 2A and 2B).
The separation of the pneumocyte layer from the
endothelial layer was further examined by staining for
the BM component, laminin. In Figure 2C, a capillary
(blue) can be seen (small arrow) which still shares its
laminin-positive BM (red) with the adjacent pneumo-
cyte layer (arrowhead). However, complete detachment
of the epithelium from this capillary is observed at the
other end of the vessel. In Figures 2C and 2D and also
in Supplementary Figure 3A, further capillaries can
be observed (large arrows) from which the adjacent
pneumocyte layer has been completely detached. It
should be noted that whilst both the naked vessel and
the adjacent detached pneumocyte layer are associated
with a laminin-positive BM, the BM associated with the
naked vessel is thicker than the pneumocyte-associated
BM and this can be seen clearly in Figures 2C
and 2D.
We also examined the presence of pneumocytes in
the metastases as a function of the lesion size. Whilst
the central area of smaller metastases contained pneu-
mocytes (Figure 2E), the central area of larger metas-
tases was generally devoid of alveolar epithelial cells
(Figure 2F). It is apparent that after they were detached
from the microvessels, these alveolar epithelial cells
underwent fragmentation and disappeared (Figure 2F).
In contrast, the denuded and incorporated microves-
sels survived. These vessels appear to be functional as
extensive BrdU incorporation was observed in tumour
cells surrounding these microvessels even in central
tumour areas (Figure 2G).
According to the angiogenic switch theory, tumours
must activate new vessel growth to grow beyond
1–2mm in size [18]. Although the majority of the
metastases that we studied in the mouse did not
reach this critical size, MAT-B-III tumours growing
in rat lung did exceed this size limit (mean diameter
3.36± 2.23mm; range 0.3–14.8mm; median 2.8mm).
To determine whether these tumours activated the
growth of new vessels, we examined these tumours
for EC proliferation. We compared the proliferation
rate of ECs in the peritumoural region (a band of
normal lung tissue 100 μm wide that was directly adja-
cent to the metastases) versus intratumoural regions
of MAT-B-III rat lung metastases. Peritumoural ECs
showed a negligible proliferation rate (1.73± 0.8%
of ECs), but the proliferation of ECs was moder-
ately increased intratumourally (12.8± 3.2%). The
difference in proliferation was statistically significant
(p< 0.05). However, we detected a slight increase
in microvessel perimeters towards the tumour core
compared with the periphery, suggesting that EC
proliferation may result in vessel dilatation (data
not shown).
Increased desmoplastic reaction towards the centre
of C38 metastases results in the transformation
of alveolar walls into intratumoural
tissue columns
As mentioned above, the C38 model of lung metastasis
demonstrated a different behaviour to the other models.
C38 tumour cells did not reinvade the alveolar walls and
thus they could not detach the pneumocytes from the
alveolar capillaries; instead, these tumours incorporated
the alveolar walls ‘as a whole’ and induced a desmo-
plastic response in them. As a result, in C38 metastases,
alveolar walls were continuously transformed into
intratumoural tissue columns (centrally located cap-
illaries embedded in connective tissue collagen and
αSMA-expressing activated fibroblasts surrounded by a
BM) (Figures 3A and 4B). These structures developed
gradually in the direction from the periphery towards
the tumour centre (Figure 3A–3D). First, in the walls
of alveoli (of which the lumens were filled with tumour
mass), αSMA-expressing activated fibroblasts appeared
(of note, no such cells – except within the arterioles
and airways – were present in the peritumoural normal
lung parenchyma). The number of activated fibroblasts
increased towards the tumour centre (Figures 3A–3D).
Consequently, the amount of deposited connective tissue
collagen and, in turn, the space between the capillaries
and the epithelium (Figures 4A and 4B) also increased.
Importantly, C38 cells did not invade this space (ie the
tissue columns); they remained in the alveolar lumens
(Figure 4C). During the development of connective
tissue columns, the epithelium facing the tumour
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Figure 2. Tumour cells split the basement membrane of the co-opted blood–gas barrier. (A, B) Electronmicrographs of a B16 lungmetastasis.
In A, a tumour cell (tu) is shown in the process of detaching the epithelium from the surface of a capillary. A wedge-shaped cellular process
of the tumour cell is advancing between the epithelial (ep) and EC (ec) layers (arrow). In B, the area where the arrow is pointing in A is
shown at high power. Note how the wedge-shaped process splits the alveolar BM into an EC-associated BM and an epithelial-associated BM.
alv= alveolar space; bm= basement membrane; ep= epithelium; ec= endothelial cell; cap= capillary lumen; tu= tumour cell. Scale bars:
(A) 2 μm; (B) 1 μm. (C, D) Images of an HT1080 lung metastasis stained formicrovessels (CD31, blue), BM (laminin, red), and pneumocytes
(podoplanin, green). The black areas are filled with tumour cells (the presence of tumour cells in these black areas within an HT1080
metastasis is demonstrated in Supplementary Figures 3A–3C). In C, on the left-hand side, a microvessel (small arrow) can be seen that is
still associated with the epithelium (arrowhead). In C, microvessels marked by large arrows are completely separated from the epithelium and
are surrounded by the tumour mass. Note that the detached alveolar epithelium (green) lies on its own BM (red). (D) A completely denuded
microvessel (arrow) within an HT1080 metastasis is shown. CD31-positive ECs (blue) are surrounded by a thick BM (laminin, red). Note that
in both C and D, the BM layer (laminin, red) that supports the podoplanin-positive epithelium (green) is thinner than the BM layer (laminin,
red) that supports the microvessels (CD31, blue). Scale bars= 20 μm. A similar area of an HT1080 metastasis stained for vimentin, laminin,
and CD31 is shown in Supplementary Figure 3A. (E, F) Image of a small (E) and a large (F) B16 metastasis stained for podoplanin (green)
and CD31 (red). In addition to the presence of blood capillaries, the smaller metastasis (E) contains centrally located sheets of alveolar
epithelium. In contrast, pneumocytes are present only at the tumour periphery in the larger metastasis (F). Arrows indicate fragmented
epithelium. The presence of numerous centrally located microvessels (red) raises the possibility of neo-angiogenesis. Scale bars= 200 μm.
H&E staining of a B16 metastasis is shown in Supplementary Figure 3D. (G) BrdU labelling (red) of an HT1080 lung metastasis. Microvessels
are highlighted by CD31 (green). BrdU-positive tumour cells are preferably localized around the microvessels (asterisks). Scale bar= 50 μm.
became gradually fragmented (Figures 4C and 4D). It is
unclear whether the BM surrounding the intratumoural
connective tissue columns was the original epithe-
lial BM or whether it was newly synthesized by the
tumour.
Presence of stromal fibroblasts and connective
tissue within the other lung metastasis models
Importantly, the distribution of αSMA-positive myofi-
broblasts and connective tissue collagen was different
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Figure 3. Increased desmoplastic reaction towards the centre of C38 metastases results in the transformation of alveolar walls into
intratumoural tissue columns (I). (A) C38 metastasis stained for CD31 to mark vessels (green), αSMA to mark activated myofibroblasts
(red), and laminin to mark the BM (blue). Black areas represent viable tumour tissue throughout the picture. Asterisks mark areas of
necrotic tissue that also appear red due to non-specific binding of the anti-mouse secondary antibody. The growing tumour is continuously
incorporating and transforming the alveolar walls (in the lower part of the picture) into tissue columns (arrows) with central microvessel(s).
Within these tissue columns, vascular remodelling and sprouting angiogenesis might also be present [43]. Note that no necrosis can be
seen at the tumour periphery where alveoli are still visible. In the alveolar walls shown in the lower right area of the picture, αSMA-positive
cells cannot be detected. Such cells appear gradually towards the tumour centre. The inset shows a column at high power with a single
central capillary. Scale bars: (A) 100 μm; (A, inset) 20 μm. (B–D) High-power micrographs of the regions marked by a single arrowhead (B),
double arrowheads (C), and triple arrowheads (D) in A. Alveolar lumens are filled with tumour cells (black areas represent the tumour mass).
The number of αSMA-positive cells (red) within the alveolar walls increases towards the centre of the tumour through B–D. These cells
are present within the alveolar walls between the epithelial BM (laminin, blue) and the capillary (CD31, green) (arrows) or between the
epithelial BMs (laminin, blue) (arrowheads). In D, note the increased number of αSMA-expressing fibroblasts (red) between the epithelial
and capillary BM layers (arrow). Scale bar: (B–D) 20 μm. The presence of tumour cells in black areas within a C38 metastasis is shown in
Supplementary Figures 3E–3G.
in HT1080, HT25, B16, C26, and MAT-B-III com-
pared with the C38 model. In these former models,
an extensive desmoplastic reaction was not observed.
αSMA-positive myofibroblasts did become incorpo-
rated into the metastases in association with the alveolar
capillaries; however, they did not participate in the
development of intratumoural tissue columns. The
αSMA-positive myofibroblasts were in close contact
with the BM of the microvessels (Supplementary
Figures 2A and 2B). A minority of these cells, however,
were denuded from the microvessels along with the
alveolar epithelial BM (Supplementary Figure 2A).
The number of αSMA-positive cells did not increase
towards the centre of the tumour in the B16 melanoma
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Figure 4. Increased desmoplastic reaction towards the centre of C38 metastases results in the transformation of alveolar walls into
intratumoural tissue columns (II). (A) Periphery of a C38 metastasis. The section is stained for CD31 (green), collagen I (red), and αSMA
(blue). The alveoli are filled with tumour cells (black areas). αSMA-positive activated fibroblasts (blue) are present in the walls of the
alveoli. Collagen I (red) is deposited in an increasing amount towards the centre of the tumour (on the left). The distribution of the
αSMA-expressing cells and the connective tissue collagen shows that the appearance of the activated fibroblasts at the tumour periphery
precedes the deposition of collagen. (B) Centre of a C38 metastasis. The section is stained for CD31 (green), collagen I (red), and TOTO-3
(blue), which highlights tumour cells. Massive and contiguous collagen I-positive connective tissue septa and columns are present within
the tumour. These structures might provide a suitable environment for sprouting angiogenesis [43]. The inset shows the co-localization of
αSMA-expressing activated fibroblasts (blue), collagen I-positive connective tissue (red), and CD31-positive ECs (green). Scale bar: (A, B)
50 μm. (C) Electron micrograph of an alveolar wall surrounded by C38 cells. The alveolar space (alv) on the right is partially filled by tumour
cells (tu). Epithelial cells (ep) cover the alveolar wall at this location. Fragmented epithelium (arrows) is present on the alveolar wall on the
left where the tumour cell (tu) is located close to the epithelial BM (bm). In the alveolar wall beside the myofibroblast (mf), connective
tissue collagen (asterisk) is also present. cap= capillary. Scale bar= 1 μm. (D) The alveolar wall shown in C. Fragments of the epithelium
(arrows) are visible between the C38 cell (tu) and the BM (bm). Scale bar (C, D): 1 μm.
and HT1080 fibrosarcoma. In contrast, the number of
activated fibroblasts increased from peritumoural lung
tissue towards the tumour centre in MAT-B-III, C26,
and especially in HT25 colon carcinoma metastases
(data not shown).
In all tumour types, the αSMA-positive activated
fibroblasts co-distributed with connective tissue colla-
gen (Supplementary Figure 2C and inset of Figure 4B).
A small amount of connective tissue collagen was
always deposited around the incorporated microves-
sels in the B16 melanoma and HT1080 fibrosarcoma
(Supplementary Figures 2C and 2D). Scattered collagen
I positivity could also be observed in the MAT-B-III
mammary carcinoma and C26 colon carcinoma metas-
tases (Supplementary Figures 2E and 2F). The HT25
colon carcinoma metastases contained larger amounts
of collagenous connective tissue (Supplementary
Figure 2G).
Lung metastases develop an arterial blood supply
Because the lung has a dual circulation system, we also
analysed the origin of the blood supply of lung metas-
tases. The anastomosis system between the bronchial
and the pulmonary circulation is quite similar to that
observed previously by us in the mouse liver [28].
Accordingly, we applied the same corrosion casting
method [28]. In accordance with other investigators
[26,27], we could not identify bronchial arteries down-
stream from the main bronchi in mice (data not shown).
Therefore, we used the MAT-B-III rat mammary car-
cinoma system. In the rat lung, only the main arterial
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Figure 5. Lung metastases develop an arterial blood supply. (A–D) Corrosion casting of MAT-B-III mammary carcinoma metastases within
rat lungs. A and B show the right lower pulmonary lobe with metastases before (A) and after (B) corrosion. The lung was filled first through
the pulmonary artery (blue), followed by filling through the bronchial arterial system (red). The lobe contains three metastases with and one
without a bronchial arterial blood supply (arrows and arrowhead, respectively). Because the metastasis in the upper part of the picture was
incompletely filled, only part of it is visible after corrosion. (C) The left pulmonary lobe with metastases after corrosion. For better visibility,
branches of the pulmonary system were removed. Three metastases with a bronchial arterial blood supply (arrows) are visible. Each has
its own branch of the bronchial artery (arrowheads). (D) Metastasis with an arterial blood supply. Note the central position of the feeding
artery (arrow).
branches could be filled and thus it was not possible to
decide whether segmental bronchi have an arterial blood
supply. Investigating the origin of the blood supply in
metastases with different sizes, we found that 95% of
the metastases with a diameter greater than 5mm had an
arterial blood supply and that 97% of themetastases with
a diameter less than 3mm had a pulmonary blood supply
(Figures 5A and 5B). Sixty-five per cent of the arterioles
supplying the tumour cells were centrally positioned in
the metastases (Figures 5C and 5D). We also compared
the proliferation rate of the metastatic cells: the tumour
cell labelling index of metastases with a bronchial blood
supply was significantly higher than that of metastases
with a pulmonary blood supply (43.5± 6.1% versus
35.3± 2.5%, respectively; mean±SD; p< 0.05).
Discussion
Experimental lung metastases can vascularize using
vessel co-option
Angiogenesis (the development of new blood vessels
from pre-existing ones) has long been regarded as cru-
cial for tumour growth [16–18,29]. However, it is
today obvious that tumours can acquire their blood sup-
ply via alternative (non-sprouting) mechanisms [10],
including glomeruloid microvessel growth [30], vas-
culogenic mimicry [31], intussusceptive microvascular
growth [32], postnatal vasculogenesis [33], and ves-
sel co-option [34]. In particular, there are also reports
on the presence and clinical significance of alterna-
tive vascularization mechanisms in the lungs. Tanaka
et al demonstrated that glomeruloid vessel formation
was associated with an aggressive angiogenic phenotype
and significantly reduced survival in NSCLC patients
[35]. Wu et al identified vasculogenic mimicry in 35%
of NSCLC patients and, furthermore, provided evidence
for an association of vasculogenic mimicry with clin-
ical outcome in this malignancy [36]. Although intus-
susceptive microvascular growth was first observed in
the growing postnatal lung [37,38] and then also dur-
ing postpneumonectomy lung growth [39], there are no
reports on this mechanism in pulmonary malignancies.
Altogether, however, vessel co-option is the most fre-
quently reported vascularization mechanism in human
lung tumour pathology studies [19–24].
In the present study, we analysed the vasculariza-
tion process in six different experimental models of
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Figure 6. Legend on the next page.
lung metastasis. Strikingly, in all models utilized, the
tumours became vascularized via the process of vessel
co-option. All of the investigated cell lines incorpo-
rated the pre-existing host tissue capillaries within
the alveolar walls, without morphological signs of
active peritumoural EC sprouting. This latter finding is
further supported by our observation that peritumoural
ECs exhibited a low proliferation rate. The absence of
peritumoural EC sprouting is most probably due to the
high pulmonary tissue capillary densities and, moreover,
to the lack of a suitable amount of connective tissue
matrix in the alveolar walls [40,41]. It is possible, how-
ever, that intratumoural EC sprouting may occur at later
stages of tumour development (provided that suitable
connective tissue is available within the more central
areas of the metastases). This assumption is supported
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by our finding of significantly elevated intratumoural
EC proliferation (versus the peritumoural lung) in
the MAT-B-III rat mammary carcinoma metastases.
Nevertheless, in addition to providing a source of new
capillary production, the elevated EC proliferation may
merely lead to vessel dilatation. In support of this, we
previously showed that something similar occurs in a
murine skin melanoma model [34].
Tumour cells of experimental lung metastases can
strip the epithelium from co-opted blood vessels
A striking finding from this study is the observation
that tumour cells can strip the epithelium from the
co-opted alveolar walls. This was observed in the
B16, HT1080, HT25, C26, and MAT-B-III models.
In these tumour types, malignant cells were observed
to invade into the alveolar walls and migrate between
the endothelial and epithelial layers (Figure 6). After
splitting occurred, the tumour cells attached firmly
to both the endothelial-associated BM layer and the
epithelial-associated BM layer. The stripped epithelial
cells were highly compressed and then underwent a
process of fragmentation and disappeared from the
metastasis, whereas the denuded capillaries remained
functional and were able to ensure the blood supply of
the metastases. The split of the alveolar BM by cancer
cells is an unusual phenomenon which we do not believe
has been described before. The exact molecular mech-
anism through which this process occurs is currently
unclear, but presumably involves selective adhesion
between the tumour cells and the BM of the blood–gas
barrier, as well as the expression of proteases that may
be acting to digest the BM in a highly selective fashion
to split the BM in two.
In the invasively growing cell lines, the majority
of alveolar wall fibroblasts remained associated with
the capillaries. However, we do not believe that they
were functioning as pericytes as they did not have BM
coverage. Instead, we propose that they were only
responsible for collagen deposition within the metas-
tases. This finding might be important because pericyte-
free capillaries may be more vulnerable against VEGF
withdrawal than their normal counterparts [42].
Generation of desmoplastic tissue columns in the
C38 lung metastasis model
Tumour cells of the C38 lung metastasis model also
incorporated the alveolar walls. However, instead of
re-invading the alveolar interstitium, these cells elicited
a desmoplastic response within the incorporated alve-
olar walls resulting in the transformation of alveo-
lar walls into microvessel-containing connective tissue
columns. The activation and increased number of inter-
stitial fibroblasts (and the accompanying collagenous
matrix deposition) at the tumour periphery led to the
gradual widening of the space between the two BM
layers (endothelial and epithelial/tumoural) towards the
tumour centre. This process assumes that the BM of the
blood–gas barrier in this tumour type is dissected into
two layers by the proliferating myofibroblasts. In par-
allel, the alveolar epithelium became fragmented and
disappeared and thus C38 cells could attach directly to
the BM left over by the epithelial cells. It is also pos-
sible that C38 cells synthesized their own BM mate-
rial onto the original BM. Although we do not have
specific antibodies against these BMs, the latter sce-
nario is indeed more probable as C38 cells in other
locations always synthesize their own BM onto the sur-
face of the incorporated connective tissue [43]. In either
case, C38 cells use BM material as a substrate for their
growth.
All in all, the transformation process of the alve-
olar walls in the C38 model culminated in the
appearance of connective tissue columns with a single
Figure 6. Schematic representation of the vascularization process in lung metastases. (A) The common steps of the vascularization process
among the different lung metastasis models utilized in this study are shown. A tumour cell arrested in a lung capillary extravasates into the
alveolar interstitium (tumour cell #1). After forming small colonies in the interstitial connective tissue (tumour cells #2 and #3), tumour
cells enter the alveolar lumen (tumour cell #4) and proliferate further there (tumour cells #5 and #6) (also see refs 50–54). Note that
where connective tissue material is present in the alveolar walls, the BM of the blood–gas barrier is separated into an endothelial BM
layer and an epithelial BM layer also in the tumour cell-free part of the alveolar wall. Of note, since the tumour mass advances from one
alveolar lumen to another, the events depicted in B–D take place in alveoli distant from the first entrapped alveolus. (B–D) The invasively
growing tumour cell lines (B16, HT1080, HT25, C26, and MAT-B-III) acquire their blood vasculature by stripping the alveolar capillaries
from the epithelium. (B) Tumour cells proliferate intensively in the occupied alveolar lumens and (re-)invade the alveolar wall connective
tissue (tumour cell #1). (C) Tumour cells in the alveolar walls start to detach the epithelium (together with the epithelial BM) from the
capillaries (tumour cells #1–3). This process culminates in the appearance of completely denuded capillaries (middle capillary) surrounded
by tumour cells. The two other capillaries are still partly covered by the epithelium. (D) Capillaries are denuded and completely surrounded
by tumour cells. Remnants of the fragmented epithelium are scattered within the tumour mass. (B’–D’) Vascularization of C38 colon cancer
metastases is accompanied by a desmoplastic response in the co-opted alveolar walls. In B’–D’, the alveolar spaces depicted are distant
from the initial extravasation place; B’–D’ represent areas in the direction from the periphery towards the centre of the metastases. (B’)
C38 cells proliferate in the alveolar lumens at the periphery of the metastases. In the walls of the occupied alveolar spaces, fibroblasts
become activated (αSMA-expressing myofibroblasts) but deposition of collagen is not yet started. (C’) Towards the centre of the metastases,
a desmoplastic response is elicited in the alveolar walls: the number of myofibroblasts increases and collagenous connective tissue matrix is
deposited. (D’) As the incorporated alveolar walls get closer to the centre of the metastases, they undergo further ‘processing’. The tumour
mass divides the desmoplastic alveolar wall into pieces, leading to the appearance of separate intratumoural connective tissue columns.
Pneumocytes are fragmented (this process can be seen on the surface of the connective tissue column on the left side of the picture) and
the tumour cells attach to the residual BM of the pneumocytes or synthesize their own BM onto the surface of the extracellular matrix of
the tissue columns. Throughout the drawings, parallel black lines represent collagen bundles in the connective tissue.
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central microvessel. Although the final steps of tissue
column development are unclear, one possibility is that
the originally incorporated alveolar walls with more
microvessels are further ‘processed’ by the tumour,
which may split the tissue columns into more parts
until the single microvessel stage is reached. However,
this assumes continuous myofibroblast proliferation
and connective tissue deposition. It is also important
to mention that sprouting of connective tissue column
capillaries following collagenous matrix deposition is
also possible, as demonstrated previously by our group
in C38 liver metastases [43].
Arterialization of lung metastases
In a recent study, we found that mouse liver metastases
inevitably become arterialized [28]. The results of
the present study suggest that pulmonary metastases
develop an arterial blood supply as well. The growing
tumour incorporates a high-pressure bronchial vessel
which, akin to hepatic arterioles, frequently acquires
a central intratumoural position. Thus, the process is
similar to that of the hepatic metastases, where it is
purely mechanical in nature, governed by the pressure
relationships in the liver vasculature. The key step in
the process of liver metastasis arterialization is the
fusion of the sinusoids at the tumour–liver parenchyma
interface [28]. Although we could not confirm a similar
phenomenon (ie capillary fusion) in the present study,
chances are that where the disruption of sphincters
between the sinusoids and terminal arterioles resulted
in an increase in the intratumoural blood pressure,
metastatic tumour cells were also likely to damage the
Sperr arteries (short arterial segments that can con-
nect the bronchial and pulmonary circulation) [44,45],
which in turn may let the high-pressure bronchial
arterial bloodstream enter the vascular system of the
metastases.
MAT-B-III cells of arterialized metastases had a sig-
nificantly higher proliferation rate than those of tumours
supplied with pulmonary blood. Although the mech-
anisms that result in the relatively lower tumour cell
proliferation rate in the metastases with a pulmonary
blood supply are not completely understood, a possi-
ble explanation can be deducted from several studies
demonstrating that hypoxia can slow down or even com-
pletely inhibit tumour cell proliferation both in vitro and
in vivo [46–48]. It is also important to note that there
should be other factors influencing the proliferation rate
of metastatic cells besides the origin of the blood supply.
For example, the proliferation rate of 3LL-HH and C38
cells of liver metastases with a baseline labelling index
above 50% was not accelerated further by arterial blood
[28]. In contrast, hepatic A2058 melanoma metastases
[28] and pulmonary MAT-B-III breast cancer metas-
tases had a relatively lower labelling index which could
be further increased by a switch from portal to arterial
and from a pulmonary to a bronchial blood supply,
respectively.
Consequences for the clinical management of lung
metastases
Metastasis to the lungs is a key event in malignant
disease outcome and the treatment of pulmonary metas-
tases remains a major clinical challenge [5–9]. Our
study describes the mechanism of vascularization of
pulmonary metastases and provides the first experimen-
tal evidence that similar to primary human non-small
cell lung cancers [19,21] and lung metastases of human
breast, colorectal, and renal cancer [20,22,24], these
tumours can co-opt the host alveolar capillaries during
their growth. Our study, however, does not only provide
evidence that the characteristic ‘alveolar growth pattern’
described in human pulmonary metastases [20,24] can
be mimicked in appropriate in vivo models but also
raises serious questions regarding the utility of using
anti-angiogenic agents for the treatment of lung metas-
tases. The conventional generation of anti-angiogenic
agents, such as bevacizumab and sunitinib, is designed
to target the process of sprouting angiogenesis and it
is unclear whether these therapies would be successful
against lung metastases that vascularize via vessel
co-option.
Novel invasive strategies including transcatheter
chemoembolization therapies have been developed
recently to improve the clinical management of pul-
monary metastases [9,49]. Importantly, it is unclear
if primary and secondary lung tumours have a pul-
monary and/or a bronchial blood supply. Accordingly,
there is no established protocol for chemoemboliza-
tion in these settings (ie it remains to be investigated
if these tumours should be catheterized/perfused
via the pulmonary or the bronchial system) [9,49].
Our results show that tumour size influences the
extent of the pulmonary versus arterial blood sup-
ply that a lung metastasis receives, which may be an
important consideration for the future application of
transcatheter chemoembolization therapies in secondary
lung tumours.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Supplementary materials and methods.
Table S1. Primary antibodies and fluorescent dyes used for immunofluorescence.
Figure S1. Tumour cells strip the alveolar epithelium from co-opted vessels.
Figure S2. Connective tissue localization within lung metastasis of HT1080, B16, MAT-B-III, C26, and HT25 cell lines.
Figure S3. Relationship between the metastatic tumor mass and the fine structure of the lungs.
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